your badges 52W Range $3–$6 7% of range Analyst Rating STRONG BUY 17 analysts Price Target $14 +386% upside P/E -1.7 ROE -167.4% Net Profit Margin ·

LRMR Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $2.96
Market Cap (MRQ) $307M
P/E -1.7
EPS $-1.32
ROE -167.4%
52W Range $3–$6

LRMR Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

About Larimar Therapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees71 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue·
2016-12-31 → 2019-12-31
EPS$-1.32
2020-12-31 → 2024-12-31
Free Cash Flow$-113M
2016-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend LRMR 5Y avg Peer Median Verdict
P/E -1.75Y avg ≈-3.4 ≈-3.4 · ·
P/B (MRQ) 2.45Y avg ≈2.5 ≈2.5 1.9 Overvalued
Price / FCF -2.25Y avg ≈-4.6 ≈-4.6 · ·
Price / Cash Flow -2.25Y avg ≈-4.7 ≈-4.7 · ·
Price / Tangible Book 3.15Y avg ≈2.5 ≈2.5 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -7.7%
Next Report Nov 03, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 12, 2026 $-0.30 $-0.39 22.8%
March 31, 2026 May 14, 2026 $-0.31 $-0.55 43.2%
Dec. 31, 2025 $-0.73 $-0.52 -41.2%
Sept. 30, 2025 $-0.61 $-0.41 -48.0%
June 30, 2025 $-0.41 $-0.49 16.3%
March 31, 2025 $-0.46 $-0.43 -7.8%
Dec. 31, 2024 $-0.45 $-0.32 -39.1%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 202520242023202220212020201920182017201620152014
Revenue ······$0$0$0$0$0$0
R&D Expense $154M$73M$28M$24M$38M$31M$21M$48M$41M$40M$55M$27M
SG&A Expense $18M$18M$14M$12M$12M$11M$2M$13M$12M$18M$19M$8M
Operating Expenses $172M$91M$42M$37M$50M$43M$23M$61M$53M$58M$74M$36M
Operating Income $-172M$-91M$-42M$-37M$-50M$-43M$-23M$-61M$-53M$-58M$-74M$-36M
Interest Expense ······$2M$2M$165.0K$529.0K$806.0K$870.0K
Interest Income ······$2M$2M$996.0K···
Other Non-op $7M$10M$5M$1M$-171.0K$322.0K$82.0K$-246.0K$971.0K$347.0K$-473.0K$-946.0K
Pretax Income $-166M$-81M$-37M$-35M$-51M$-42M$-23M$-61M$-52M$-58M$-74M$-36M
Income Tax $0$0$0$0$0$0$0$0$0$0$0$0
Net Income $-166M$-81M$-37M$-35M$-51M$-42M$-23M$-61M$-52M$-58M$-74M$-36M
EPS (Basic) ·$-1.32$-0.84$-1.37$-2.95$-3.57······
EPS (Diluted) ·$-1.32$-0.84$-1.37$-2.95$-3.57······
Shares (Basic) ·61,256,08443,901,24125,761,39417,164,28411,883,155······
Shares (Diluted) ·61,256,08443,901,24125,761,39417,164,28411,883,155······
EBITDA $-172M$-91M$-42M$-37M$-50M$-43M$-46M$-61M$-53M$-58M·$-36M
Balance Sheet 23
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $85M$33M$27M$27M$70M$68M$1M$49M$41M$32M$36M$58M
Prepaid Expense $5M$12M$3M$2M$2M$5M$4M$2M$2M$1M$2M$1M
Current Assets $142M$195M$90M$121M$72M$98M$5M$121M$105M$131M$188M$117M
PP&E (Net) $622.0K$881.0K$684.0K$831.0K$1M$1M$274.0K$375.0K$528.0K$661.0K$902.0K$79.0K
PP&E (Gross) $3M$2M$2M$2M$2M$1M$453.0K$925.0K$1M$981.0K$1M$129.0K
Accum. Depreciation $2M$2M$1M$914.0K$596.0K$335.0K$179.0K$550.0K$508.0K$320.0K$120.0K$50.0K
Other Non-current Assets $523.0K$596.0K$659.0K$638.0K$669.0K$419.0K$90.0K$57.0K$57.0K$61.0K$94.0K$242.0K
Total Assets $146M$200M$96M$126M$79M$105M$5M$122M$106M$132M$189M$118M
Accounts Payable $5M$2M$1M$2M$2M$3M$4M$4M$3M$3M$7M$2M
Accrued Liabilities $58M$21M$7M$8M$7M$6M$2M$4M$4M$4M$6M$3M
Short-term Debt ······$7M$5M·$4M$3M$1M
Current Liabilities $65M$24M$10M$11M$9M$9M$6M$13M$7M$10M$17M$7M
Capital Leases $3M$4M$5M$5M$5M$6M$6M·····
Total Liabilities $68M$28M$14M$16M$14M$15M$6M$28M$27M$10M$20M$13M
Long-term Debt ······$15M$20M$20M$3M··
Total Debt ······$7M$5M·$4M·$1M
Common Stock $83.0K$64.0K$43.0K$43.0K$18.0K$15.0K$6.0K$37.0K$27.0K$27.0K$27.0K$23.0K
Paid-in Capital $513M···········
Retained Earnings $-435M$-269M$-189M$-152M$-116M$-66M$-23M$-351M$-290M$-238M$-180M$-105M
AOCI $54.0K$148.0K$81.0K$-31.0K·$1.0K$35.0K$-33.0K$-58.0K$-80.0K$-207.0K$-35.0K
Stockholders' Equity $78M$172M$82M$111M$64M$90M$-694.0K$3M$78M$122M$169M$104M
Liabilities + Equity $146M$200M$96M$126M$79M$105M$5M$122M$106M$132M$189M$118M
Shares Outstanding 83,090,39263,815,06543,909,06943,269,20017,710,45015,367,7306,091,25037,287,22127,489,45727,332,55127,242,50322,879,160
Cash Flow 11
Metric Trend 202520242023202220212020201920182017201620152014
Stock-based Comp $7M$9M$8M$7M$5M$2M$129.0K$10M$8M$10M$9M$2M
Restructuring ······$6M··$1M··
Operating Cash Flow $-113M$-71M$-33M$-28M$-42M$-42M$-23M$-51M$-44M$-52M$-60M$-28M
CapEx $91.0K$515.0K$164.0K$100.0K$333.0K$62.0K$83.0K$108.0K$55.0K$660.0K$595.0K$58.0K
Investing Cash Flow $100M$-85M$33M$-91M$24M$17M$-83.0K$-7M$36M$51M··
Stock Issued $65M$162M·$75M$20M$76M·$65M··$130M$103M
Net Stock Activity $65M$162M·$75M$20M$76M·$65M····
Financing Cash Flow $65M$162M$30.0K$75M$20M$94M$19M$67M$17M$-3M··
Net Change in Cash $52M$6M$-76.0K$-43M$2M$68M$-3M$9M$8M$-3M$-23M$23M
Free Cash Flow $-113M$-71M$-34M$-28M$-42M$-42M$-42M$-52M$-44M$-53M·$-28M
Levered FCF ······$-43M$-53M$-44M$-53M·$-29M
Profitability 3
Metric Trend 202520242023202220212020201920182017201620152014
ROA -95.8%-54.4%-33.2%-34.5%-55.2%-77.3%-44.9%-54.0%-43.9%-36.1%·-46.9%
ROE -167.4%-43.5%-42.4%-30.8%-74.2%-44.2%-163.6%-62.2%-52.0%-39.8%·-203.4%
ROIC -220.9%-52.9%-51.1%-32.9%-78.3%-47.7%-75.0%-61.9%-67.8%-46.5%·-33.6%
Liquidity & Solvency 4
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 2.28.09.511.38.210.95.99.114.413.2·17.0
Quick Ratio 1.31.42.82.57.97.62.23.75.63.3·8.4
Debt / Equity ······0.10.1·0.0·0.0
Interest Coverage ······-25.9-32.2-321.2-110.1·-40.8
Efficiency 1
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover ······0.00.00.00.0·0.0
Per Share 4
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $0.94$2.69$1.86$2.56$3.64$5.84$1.43$2.50$2.85$4.45·$4.56
Cash Flow / Share ·$-1.16$-0.76$-1.07$-2.45·······
Cash / Share $1.03$0.52$0.61$0.62$3.96$4.43$0.73$1.32$1.48$1.18·$2.54
EPS (TTM) $-1.72$-1.32$-0.84$-1.37$-2.95$-3.57······
Valuation (TTM) 12
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $0$0$0$0$0$0$0$0$0$0$0$0
Net Income TTM $-166M$-81M$-37M$-35M$-51M$-42M$-23M$-61M$-52M$-58M$-74M$-36M
Market Cap $317M$247M$200M$179M$191M$329M$499M$2.21B$1.52B$1.04B·$8.47B
Enterprise Value ······$479M$2.17B·$1.01B·$8.41B
P/E -2.2-2.9-5.4-3.0-3.7-6.0······
P/B 4.11.42.41.63.03.79.323.719.58.6·81.1
P / Tangible Book 4.11.42.41.63.03.7······
P / Cash Flow -2.8-3.5-6.0-6.5-4.5-7.8-12.2-43.0-34.8-20.1·-299.8
P / FCF -2.8-3.5-5.9-6.5-4.5-7.8-12.0-42.9-34.8-19.8·-299.2
EV / EBITDA ······-10.5-35.5·-17.4·-236.7
EV / FCF ······-11.5-42.1·-19.3·-297.2
Earnings Yield -45.1%-34.1%-18.5%-33.2%-27.3%-16.7%······

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Net Income $-166M $-81M $-37M $-35M $-51M
Diluted EPS · $-1.32 $-0.84 $-1.37 $-2.95

Institutional owners (13F) 178 filers · $309.2M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 178
Value held $309.2M
New positions 31
Exited positions 29
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
31 (-21 vs prior Q) 29 (+15 vs prior Q) 70 (+12 vs prior Q) 44 (+3 vs prior Q) +7.7M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
DEERFIELD MANAGEMENT COMPANY, L.P. $108,601,271 35,606,974 35.13% Shares
Blue Owl Capital Holdings LP $27,947,629 9,163,157 9.04% Shares
BlackRock, Inc. $17,318,006 5,678,035 5.60% Shares
VANGUARD GROUP INC $11,606,083 3,046,216 3.75% Shares
Defilade Capital Management, L.P. $11,193,912 3,670,135 3.62% Shares
Driehaus Capital Management LLC $9,648,440 3,163,423 3.12% Shares
VANGUARD CAPITAL MANAGEMENT LLC $9,073,448 2,974,901 2.93% Shares
RTW INVESTMENTS, LP $7,826,297 2,565,999 2.53% Shares
AQR CAPITAL MANAGEMENT LLC $7,232,813 2,371,414 2.34% Shares
MARSHALL WACE, LLP $6,137,996 2,012,458 1.99% Shares
DAFNA Capital Management LLC $6,124,900 2,008,164 1.98% Shares
GOLDMAN SACHS GROUP INC $5,346,375 1,752,910 1.73% Shares
GEODE CAPITAL MANAGEMENT, LLC $5,121,921 1,679,003 1.66% Shares
Qube Research & Technologies Ltd $5,005,178 1,641,042 1.62% Shares
CITADEL ADVISORS LLC $4,443,316 1,456,825 1.44% Shares
STATE STREET CORP $4,306,002 1,411,804 1.39% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $4,279,675 1,403,172 1.38% Shares
Woodline Partners LP $4,272,593 1,400,850 1.38% Shares
MILLENNIUM MANAGEMENT LLC $4,065,763 1,333,037 1.32% Shares
DIMENSIONAL FUND ADVISORS LP $2,932,299 961,083 0.95% Shares
FMR LLC $2,858,971 937,368 0.92% Shares
SPHERA FUNDS MANAGEMENT LTD. $2,824,312 926,004 0.91% Shares
Nuveen, LLC $2,730,677 895,304 0.88% Shares
Alyeska Investment Group, L.P. $1,882,494 617,211 0.61% Shares
NORTHERN TRUST CORP $1,678,311 550,266 0.54% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1,580,815 518,300 0.51% Put option
VANGUARD FIDUCIARY TRUST CO $1,366,912 448,168 0.44% Shares
Fi3 FINANCIAL ADVISORS, LLC $1,263,896 2,915 0.41% Shares
LOS ANGELES CAPITAL MANAGEMENT LLC $1,218,604 399,542 0.39% Shares
SummitTX Capital, L.P. $1,074,466 352,284 0.35% Shares
JPMORGAN CHASE & CO $1,049,648 328,015 0.34% Shares
Gem Investment Advisors, LLC $974,533 319,519 0.32% Shares
Burkehill Global Management, LP $915,000 300,000 0.30% Shares
RENAISSANCE TECHNOLOGIES LLC $907,201 297,443 0.29% Shares
HAP Trading, LLC $848,766 262,776 0.27% Shares
ADAR1 Capital Management, LLC $831,872 272,745 0.27% Shares
Cerity Partners LLC $828,326 271,582 0.27% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $821,975 269,500 0.27% Call option
CITADEL ADVISORS LLC $732,610 240,200 0.24% Put option
TWO SIGMA INVESTMENTS, LP $720,206 236,133 0.23% Shares
Seven Fleet Capital Management LP $704,309 230,921 0.23% Shares
HAP Trading, LLC $687,173 237,776 0.22% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $631,255 206,969 0.20% Shares
IEQ CAPITAL, LLC $620,258 203,363 0.20% Shares
Caption Management, LLC $588,705 193,018 0.19% Shares
Soleus Capital Management, L.P. $573,711 188,102 0.19% Shares
Cubist Systematic Strategies, LLC $523,775 162,159 0.17% Shares
JACOBS LEVY EQUITY MANAGEMENT, INC $520,254 170,575 0.17% Shares
Susquehanna Portfolio Strategies, LLC $503,726 165,156 0.16% Shares
ALLIANCEBERNSTEIN L.P. $486,990 108,220 0.16% Shares

Show all 178 institutional owners →

Activists & 5%+ owners 3 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Partners, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., James E. Flynn ×12 filings March 2, 2026 34.41% Amendment Passive investment SEC
Chondrial Therapeutics Holdings, LLC ×2 filings June 30, 2020 · Initial filing · SEC
Chondrial Therapeutics, Inc. Dec. 27, 2019 · Initial filing M&A / sale SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 29 insiders · 13 officers · 18 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Carole Ben-Maimon President and CEO Jan. 26, 2026 A 368,276 0 0 $0
Jeffrey S. Hatfield Chief Executive Officer Jan. 22, 2019 A · 0 0 $0
Michael Celano Chief Financial Officer Jan. 26, 2026 A 215,785 0 0 $0
Patricia L Allen Chief Financial Officer Jan. 22, 2019 A 19,793 0 0 $0
John B. Harlow Jr. President and COO Sept. 29, 2026 A 50,000 0 0 $0
Thomas E. Hughes President and Chief Scientific Officer June 28, 2018 S 125,247 0 0 $0
Patrick Loustau President March 31, 2016 A · 0 0 $0
Gopi Shankar Chief Development Officer Jan. 26, 2026 A 76,443 0 0 $0
Russell Clayton Chief Medical Officer Jan. 26, 2026 A 71,443 0 0 $0
Singhal Priya Head of Research & Development April 2, 2019 A · 0 0 $0
Brian Mcveigh Chief Business Officer Jan. 22, 2019 A · 0 0 $0
Dennis D Kim Chief Medical Officer Jan. 22, 2019 A 21,443 0 0 $0
Alicia Secor Chief Commercial Officer March 31, 2016 A 0 0 0 $0
Thomas Edward Hamilton Director July 6, 2026 P 714,798 2 0 $667,000
Joseph Truitt Director May 19, 2026 A 2,750 0 0 $0
Frank E Thomas Director May 19, 2026 A 7,000 1 0 $25,000
Jeffrey W Sherman Director May 19, 2026 A 5,000 1 0 $25,000
Jonathan S Leff Director May 19, 2026 A · 0 0 $0
Peter Barrett Director May 10, 2022 A 4,643,327 0 0 $0
Thomas O Daniel Director May 12, 2021 A 19,452 0 0 $0
Wendy Everett Director June 26, 2019 A · 0 0 $0
Cameron Geoffrey Mcdonough Director June 26, 2019 A 0 0 0 $0
Robert J Perez Director June 26, 2019 A 5,322 0 0 $0
John L Lamattina Director June 26, 2019 A 31,376 0 0 $0
Bruce Booth Director Jan. 3, 2018 A 4,638,028 0 0 $0
Frances K Heller Director Oct. 13, 2017 P 47,961 0 0 $0
Kevin P Starr Director Sept. 24, 2015 J 370,323 0 0 $0
Avi Y. Goldberg Director Sept. 18, 2015 S 53,734 0 0 $0
CHONDRIAL THERAPEUTICS HOLDINGS, LLC 10% owner June 26, 2020 J 8 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 21 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IBRN · iShares Trust 0.21% 4,010 SH Sept. 11, 2026 Daily
OMFS · Invesco Exchange-Traded Self-Indexe… 0.11% 92,953 SH Oct. 2, 2026 Daily
IWC · iShares Trust 0.06% 225,822 SH Sept. 11, 2026 Daily
IBBQ · Invesco Exchange-Traded Fund Trust … 0.02% 7,348 SH Oct. 2, 2026 Daily
IWO · iShares Trust 0.02% 625,151 SH Sept. 11, 2026 Daily
IBB · iShares Trust 0.01% 394,961 SH Sept. 11, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.01% 382,844 SH Aug. 19, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.01% 71,780 SH Aug. 19, 2026 Daily
DFAS · Dimensional ETF Trust 0.01% 340,789 NS July 31, 2026 N-PORT
IWM · iShares Trust 0.01% 1,693,182 SH Sept. 11, 2026 Daily
RSSL · Global X Funds 0.01% 31,780 NS July 31, 2026 N-PORT
DXUV · Dimensional ETF Trust 0.00% 4,394 NS July 31, 2026 N-PORT
DFSU · Dimensional ETF Trust 0.00% 12,923 NS July 31, 2026 N-PORT
DCOR · Dimensional ETF Trust 0.00% 11,721 NS July 31, 2026 N-PORT
DFAC · Dimensional ETF Trust 0.00% 105,245 NS July 31, 2026 N-PORT
IWV · iShares Trust 0.00% 17,386 SH Sept. 10, 2026 Daily
DFAU · Dimensional ETF Trust 0.00% 11,156 NS July 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.00% 699,471 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 2,206,446 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 7,400 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.00% 172,125 SH Aug. 19, 2026 Daily

LRMR Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 17 analysts BUY
Median target $13.00 +339.2%
8 47.1% Strong Buy
8 47.1% Buy
1 5.9% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

10 analysts · 2026-09-29

Mean target $14.40 +386.5%

← Below all targets Current price $2.96
Low$5.00 Mean$14.40 High$26.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
LRMR $317M -2.2 · · -167.4% ·
BBOT $1.00B -2.9 · · -146.2% ·
BNTC $460M -13.7 · · -25.0% ·
SCTX · · · · · ·
CABA $220M -1.0 · · -115.5% ·
PRLD · -2.2 73.4% -819.6% -137.7% ·
LXEO $725M -5.3 · · -51.9% ·
ABEO $290M 5.2 147.5% 1223.1% 44.1% ·
VNDA $521M -2.4 8.7% -102.0% -54.2% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 4, 2026